Nolvadex D (Tamoxifen Citrate)

Tamoxifen citrate, the active ingredient in Nolvadex D, is a selective estrogen receptor modulator presented as an oral formulation for oral use. It is employed in the treatment of estrogen receptor‑positive breast cancer and in the prevention of breast cancer in high‑risk women. GNH USA supplies Nolvadex D as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Tamoxifen citrate acts on estrogen‑dependent pathways in breast tissue and is indicated for several oncologic indications. - Estrogen receptor‑positive breast cancer (adjuvant and metastatic): improves disease‑free survival and reduces tumor progression. - High‑risk women for breast cancer prevention: lowers the incidence of invasive breast cancer. - Ductal carcinoma in situ after surgery: decreases the risk of local recurrence.

Tamoxifen citrate may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Hot flashes: transient sensation of warmth and sweating. - Nausea: mild to moderate upset stomach. - Menstrual irregularities: changes in cycle length or flow. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Endometrial carcinoma: abnormal uterine bleeding indicating possible cancer. - Severe liver injury: jaundice, elevated liver enzymes, or hepatic failure.

When using Tamoxifen citrate, clinicians should observe several safety measures. - Monitor hepatic function: obtain baseline liver tests and repeat periodically. - Assess thromboembolic risk: avoid in patients with a history of clotting disorders. - Evaluate uterine health: consider gynecologic assessment for postmenopausal women. - Pregnancy considerations: avoid use during pregnancy and discuss effective contraception. - Drug interactions: review concomitant medications for CYP2D6 inhibitors. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Tamoxifen citrate interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase tamoxifen plasma levels and toxicity. - Warfarin: tamoxifen can enhance anticoagulant effect; monitor INR closely. - Aromatase inhibitors: opposing mechanisms may reduce therapeutic benefit.

Moderate Interactions (Monitor Closely): - Antidepressants metabolized by CYP2D6: possible altered drug concentrations. - SSRIs that are weak CYP2D6 inhibitors (e.g., sertraline): monitor clinical response. - Certain antacids: may affect absorption; separate administration times.